Impact of health education on adherence to clopidogrel and clinical effectiveness of antiplatelet treatment in patients after myocardial infarction by Kubica, Aldona et al.
154 www.fmc.viamedica.pl
ORIGINAL ARTICLE
Aldona Kubica1, Michał Kasprzak2, Karolina Obońska2, Ewa Laskowska2, Anna Andruszkiewicz1, 
Przemysław Paciorek2
1Department of Health Promotion
2Department of Cardiology and Internal Medicine 
Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland
Impact of health education on 
adherence to clopidogrel and clinical 
effectiveness of antiplatelet treatment  
in patients after myocardial infarction
ABSTRACT
Non-adherence rates to antiplatelet drugs in patients with acute myocardial infarction (AMI) range from 
13% to 60%. We aimed to evaluate whether individual health education can improve adherence to treat-
ment with clopidogrel in patients after AMI. This was a prospective, single-center, randomized clinical 
trial with a 12-month follow-up. Patients with AMI treated with percutaneous coronary intervention (PCI) 
were enrolled. The primary endpoint was defined as non-adherence to clopidogrel during follow-up (drug 
availability ≤ 80%). Secondary endpoints included platelet function assessment, adverse cardiovascular 
(CV) events (CV death, PCI for ACS, unscheduled CV hospitalization). There were 191 patients enrolled in 
the study and divided into two groups: the individual education (IE) group (100 patients) and the standard 
treatment (ST) group (91 patients). Adherence to the treatment with clopidogrel based on the data from 
the National Health Fund did not differ significantly between the IE and ST groups [76.7% (30.7–99.7%) 
v. 84.4% (46.5–99.7%); p = 0.25]. There was a substantial difference in the prevalence of unscheduled CV 
hospitalizations between both groups, IE and ST respectively [22 (22.0%) v. 10 (11.0%); p = 0.042]. The 
rate of CV death and ACS treated with PCI during follow-up was low and did not differ between groups. 
In conclusion, the program of individual health education did not improve adherence to treatment with 
clopidogrel. The expected benefits of medication are not achievable at current levels of adherence. The 
self-reported adherence assessment is unreliable and cannot be used for effective treatment guidance. 
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Introduction
Antiplatelet therapy is the cornerstone of the treat-
ment in patients with acute coronary syndrome (ACS). 
Pharmacodynamic response to clopidogrel shows 
substantial interpatient variability. Patients with coro-
nary artery disease (CAD) and lesser platelet inhibition 
in response to clopidogrel appear to be at increased 
risk for cardiovascular events [1, 2]. Low adherence to 
treatment is probably the major cause of clopidogrel 
“resistance” [3–5]. Despite the importance of second-
ary prevention, non-adherence rates to prescribed, 
evidence-based medicines for patients with acute 
myocardial infarction (AMI) range from 13% to 60% [6]. 
Moussa and Colombo [7] highlighted the necessity of 
patients’ education regarding the risks and benefits of 
dual antiplatelet treatment to avoid premature discontin-
uation of the drug. Nevertheless, no standard approach 
has yet been developed.
The aim of this study was to evaluate whether 
individual health education can improve adherence 
to treatment with clopidogrel leading to more efficient 
inhibition of the P2Y12 receptor in patients after AMI. 
Methods 
Study population and recruitment 
This prospective, single-center, randomized clinical 
trial with a 12-month follow-up was conducted at An-
toni Jurasz University Hospital (Collegium Medicum, 
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Nicolaus Copernicus University, Bydgoszcz, Poland). 
The recruitment phase of the study was from 1st Oc-
tober 2010 until 31st October 2011. All patients with 
AMI (both ST-elevation MI and non-ST elevation MI) 
and treated with percutaneous coronary intervention 
(PCI) were screened for eligibility. The exclusion cri-
teria were defined as follows: the need for prolonged 
use of heparin or fondaparinux, oral anticoagulant 
therapy, bleeding disorders (including thrombocytope-
nia < 100 × 103/µL), anemia (HGB < 10.0 g/dL), active 
inflammation, heart failure in NYHA class III and IV, and 
life expectancy < 1 year. 
Two hundred patients, who gave informed writ-
ten consent, were randomly assigned 1:1 to receive 
additional individual educational intervention (EI) or 
standard treatment (ST). Nine patients withdrew their 
consent during follow-up (all from the ST group), thus 
the study population comprised of 191 patients, for 
whom the follow-up data were available. The study 
population characteristics are shown in Table 1. 
In-hospital management and discharge treatment 
recommendations strictly adhered to the European 
Society of Cardiology guidelines. Patients received 
a 600 mg loading dose and a 75 mg maintenance 
dose of clopidogrel in combination with aspirin doses 
of 300 mg and 75 mg, respectively. To avoid addi-
tional confounding factors, concomitant therapy was 
standardized and included bisoprolol, perindopril 
and simvastatin, if no contraindications were present. 
Before being discharged from the hospital all patients 
obtained information regarding the need for systematic 
intake of the prescribed drugs as well as the hazards 
associated with its premature termination. Additionally, 
they were provided with a written warning, enclosed in 
the discharge letter, that read: “Do not stop treatment 
prematurely! Earlier discontinuation of the treatment 
may result in stent thrombosis and sudden cardiac 
death!”. Follow-up visits were scheduled at 3, 6, and 
9 months after discharge. During every visit ADP-in-
duced platelet aggregation (ADP-PA) and vasodila-
tor-stimulated phosphoprotein phosphorylation (VASP) 
were assessed. Moreover, patients were asked to 
declare their adherence to the prescribed clopidogrel 
(systematic drug intake: YES or NO). Patients assigned 
to the EI group were scheduled for additional educa-
tional meetings with the attending physician at the end 
of hospitalization and at every follow-up visit. The intent 
of the meetings was to explain the pathophysiology and 
symptoms of CAD, to elucidate goals and potential gain 
of the treatment, and to highlight the risk of premature 
termination of antiplatelet therapy. 
Patients’ adherence to the medication regimen was 
also verified based on the data from The National Health 
Fund regarding prescribed drugs purchase. Adherence 
was defined as the proportion of drug availability (the 
number of purchased clopidogrel tablets) to drug re-
quirement (the number of clopidogrel tablets needed 
to complete the treatment = the number of follow-up 
days) and was arbitrarily judged as adequate when the 
proportion exceeded 80%. 
The primary endpoint
The primary endpoint was defined as non-adher-
ence to clopidogrel during follow-up (drug availabili-
ty ≤ 80%). 
Secondary endpoints
Secondary endpoints included platelet function 
assessment (ADP-PA, VASP), adverse cardiovascular 
(CV) events (CV death, PCI for ACS, unscheduled CV 
hospitalization, combined of any adverse CV event).
The study protocol has been approved by The Eth-
ical Committee of the Nicolaus Copernicus University. 
Platelet function assessment
The ADP-PA examination was performed using 
impedance aggregometry. Whole blood was tested 
using a Multiplate Analyzer (Medical Cyclotron, Munich, 
Germany). The platelet aggregation rate was assessed 
as the area under the curve of the aggregation curve 
(AUC) and was expressed in units of aggregation (U).
For the determination of VASP phosphorylation in whole 
blood samples, a standardized reagent — Purified 
Mouse Anti-VASP (Becton, Dickinson & Co., Franklin 
Lakes, NJ USA) and flow cytometer (Becton, Dickinson 
& Co., Franklin Lakes, NJ USA) were used. VASP was 
determined based on fluorescence of blood samples af-
ter the addition of the monoclonal antibody. The platelet 
reactivity index (PRI) was defined as the mean fluores-
cence intensity (MFI) after incubation with PGE1 and 
ADP according to the following formula: 
PRI = [(MFI(PGE1) – MFI(PGE1+ADP)/MFI(PGE1)] × 100. 
Statistical analysis
According to the Shapiro-Wilk test, the investigated 
continuous variables were non-normally distributed, 
therefore, they were reported as medians and inter-
quartile ranges (IR). For comparisons between two 
and three groups, the Mann-Whitney unpaired rank 
sum test and the Kruskal–Wallis one-way analysis 
of variance were used, respectively. Categorical 
variables were expressed as a number of patients 
presenting the given feature and a percentage of 
patients in the analysed group. Categorical variables 
were compared using the c2 test with the Yates’ cor-
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Table 1. Characteristics of the study population [data are presented as median (upper quartile–lower quartile) or 
number (percentage)]
Feature Individual education  
(n = 100)
Standard treatment  
(n = 91)
p value
Age (years) 60.0 (52.0–65.0) 61.0 (54.0–69.0) 0.06
Gender (male) 76 (76.0%) 66 (72.5%) 0.58
STEMI 86 (86.0%) 79 (86.8%) 0.87
Prior diagnosis of CAD 20 (20.0%) 28 (30.8%) 0.09
Prior MI 9 (9.0%) 10 (11.0%) 0.65
Prior PCI 7 (7.0%) 6 (6.6%) 0.91
Prior CABG 4 (4.0%) 1 (1.1%) 0.42
Prior CHF 5 (5.0%) 8 (8.8%) 0.97
BMI > 25 kg/m2 79 (79.0%) 62 (68.1%) 0.09
Arterial hypertension 55 (55.0%) 51 (56.0%) 0.88
Diabetes mellitus 26 (26.0) 41 (45.1%) 0.006
Current smokers 51 (51.0%) 48 (52.7%) 0.81
Ex-smokers 20 (20.0%) 19 (20.9%) 0.88
Family history of CAD 24 (24.0%) 26 (28.6%) 0.47
TC [mg/dL] 214.0 (178.0–241.5) 212.0 (178.0–240.0) 0.57
LDL-C [mg/dL] 133.5 (115.0–168.0) 146.0 (115.0-173.0) 0.09
LDL ≥ 115 mg/dL 74 (74.0%) 69 (75.9%) 0.85
HDL-C [mg/dL] 40.0 (34.5–46.5) 40.0 (34.0–49.0) 0.99
Tg [mg/dL] 110.0 (70.0–162.5) 95.0 (71.0–144.0) 0.41
Glycaemia [mg/dL] 131.0 (116.0–153.0) 141.0 (126.0–178.0) 0.046
HbA1c (%) 6.0 (5.8–6.3) 6.1 (5.8–6.8) 0.07
WBC [103/µL] 7.6 (6.2–9.0) 7.8 (6.8–9.7) 0.30
RBC [106/ µL] 4.5 (4.2–4.9) 4.5 (4.2-4.8) 0.67
HGB [g/dL] 13.5 (12.8–14.4) 13.5 (12.8-14.5) 0.76
HCT (%) 39.3 (37.1–41.7) 39.7 (37.0-42.5) 0.49
PLT [103/µL] 207.0 (177.0–251.5) 208.0 (172.0–232.0) 0.28
MPV [fl] 10.7 (10.2–11.3) 11.0 (10.4–11.6) 0.07
BNP [pg/dL] 121.0 (69.6–233.0) 111.8 (61.0–206.0) 0.48
hsCRP [mg/L] 11.9 (5.6–31.9) 12.1 (3.8–29.7) 0.52
Angiographic assessment 0.82
One-vessel disease 41 (41.0%) 39 (42.9%)
Two-vessel disease 27 (27.0%) 21 (23.1%)
Three-vessel disease 32 (32.0%) 31 (34.1%)
Revascularization 0.37
Complete 57 (57.0%) 57 (63.3%)
Partial 43 (43.0%) 33 (36.7%)
Further treatment 0.32
Conservative 75 (75.0%) 74 (81.3%)
PCI 20 (20.0%) 11 (12.1%)
CABG 5 (5.0%) 6 (6.6%)
Education 0.34
   Elementary or vocational 65 (65.0%) 53 (58.2%)
   Secondary or university 35 (35.0%) 38 (41.8%)
Employment status 0.80
   Employed 33 (33.0%) 33 (36.3%)
   Unemployed, pensioner or disability pensioner 67 (67.0%) 58 (63.7%)
Economic status 0.24
   Good or satisfactory 84 (84.0%) 83 (91.2%)
   Bad 16 (16.0%) 8 (8.8%)
Place of residence 0.34
   City 65 (65.0%) 65 (71.4%)
   Village 35 (35.0%) 26 (28.6%)
Patient self-assessment of knowledge regarding CAD 0.70
   Sufficient 30 (30.0%) 25 (27.5%)
   Insufficient 70 (70.0%) 66 (72.5%)
STEMI — ST-elevation myocardial infarction; CAD — coronary artery disease; MI - myocardial infarction; PCI — percutaneous coronary intervention;  
CABG — coronary artery bypass grafting; CHF — congestive heart failure; BMI — body mass index; TC — total cholesterol; LDL-C — low-density lipoprotein  
— cholesterol; LDL — low-density lipoprotein; HDL-C — high-density lipoprotein-cholesterol; Tg — triglycerides; HbA1c — glycated haemoglobin;  
WBC — white blood cells; RBC — red blood cells; HGB — haemoglobin concentration; HCT — haematocrit; PLT — platelets; MPV — mean platelet volume; 
BNP — brain natriuretic peptide; hsCRP — high sensitivity C-reactive protein
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Table 2. Adherence to clopidogrel, primary and secondary endpoints [median (upper quartile–lower quartile) or 
number (percent)]
Feature Individual education  (n = 100) Standard treatment (n = 91) p value
Adherence to clopidogrel 76.7% (30.7–99.7%) 84.4% (46.5–99.7%) 0.25
Adherence ≤ 80% 49 (49.0%) 35 (38.5%) 0.13
ADP-PA [U] 18.0 (10.0–30.0) 19.5 (11.0–29.0) 0.56
PRI (%) 54.5 (38.3–67.8) 51.9 (34.9–64.7) 0.28
CV death 0 (0.0%) 2 (2.2%) 0.44
PCI for ACS 6 (6.0%) 4 (4.4%) 0.86
Unscheduled CV hospitalization 22 (22.0%) 10 (11.0%) 0.042
Combined of any adverse CV event 
at follow-up
22 (22.0%) 14 (15.4%) 0.24
ADP-PA — ADP-induced platelet aggregation; PRI — platelet reactivity index; CV — cardiovascular; PCI — percutaneous coronary intervention; 
ACS — acute coronary syndrome
rection if required. The Cochran–Armitage test was 
used to assess the presence of a linear trend among 
categorical variables. Differences were considered 
significant at p < 0.05. The statistical analysis was 
carried out using the Statistica 10.0 package (StatSoft, 
Tulsa, USA).
Results
Patients assigned to the EI and ST groups did not 
differ significantly, with the exception of the preva-
lence of diabetes mellitus and glucose concentration 
on admission (Tab. 1). The evaluation of the patients’ 
adherence to treatment with clopidogrel based on 
the data from The National Health Fund did not 
differ significantly between both groups of patients 
(Tab. 2). However, the prevalence of non-adherence 
defined as the drug availability (≤ 80%) tended to be 
higher in EI patients when compared with ST group 
(49% v. 38.5%; p = 0.13). Interestingly, self reported 
proportion of adherence to treatment (declaration 
of systematic clopidogrel intake at each follow-up 
visit) was clearly distinct and amounted to 92% and 
95.5%, respectively. No difference between EI and 
ST patients regarding platelet function parameters re-
flecting inhibition of P2Y12 receptor was found. With 
regard to the clinical outcome, unexpected but sub-
stantial differences in the prevalence of unscheduled 
CV hospitalizations appeared. The rate of CV death 
as well as ACS treated with PCI during follow-up was 
very low and did not differ between groups. Accord-
ing to multivariate analysis, female gender was the 
only predictor of adherence to antiplatelet treatment 
OR 2.504 (95% CI 1.254–4.999, p = 0.009).
Discussion
“Drugs don’t work in patients who don’t take them” 
— C. Everett Koop, MD. Medication adherence is an 
issue of growing concern for those working to improve 
health system performance. Promoting adherence to 
medications offers a rare opportunity to simultaneously 
improve health outcomes whilst reducing costs in 
patients after AMI [8, 9]. On the basis of our previous 
experience [10–12], we assumed that individual, 
complex health education which would begin with 
hospitalization and continue during follow-up shall 
result in the improvement of patients’ adherence to the 
treatment with clopidogrel in patients after AMI. Our 
health education intervention aimed to explain patho-
physiology and symptoms of coronary artery disease, 
to elucidate goals and potential gain of the treatment 
and to highlight the risk of premature termination of 
antiplatelet therapy. However, we failed to demonstrate 
any benefits of this health education intervention.
Ferreira-González et al. [13] related 10.6% of 
non-adherence to dual antiplatelet treatment in 
1,622 consecutive patients undergoing drug eluting 
stent (DES) implantation. However, these findings were 
based on patient declarations and were not verified 
by prescription refill control. They concluded that anti-
platelet therapy discontinuation after DES implantation 
is not exceptional, it is usually temporary and does not 
appear to have a large impact on the risk [13]. Further-
more, taking into account the considerable differences 
between self-reported and verified data regarding 
prescribed drugs purchase revealed in our study, we 
can doubt the veracity of these results. The Myocardi-
al Ischaemia National Audit Project Registry and the 
General Practice Research Database revealed that out 
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of the 7543 patients after AMI only 68.6% with non-ST-
segment elevation myocardial infarction (NSTEMI) and 
62.8% with ST-segment elevation myocardial infarction 
(STEMI) received a clopidogrel prescription in the first 
3 months after discharge from the hospital. The adjust-
ed odds of prescribed clopidogrel at 12 months were 
similar after NSTEMI 53% (95% CI 51–55) and STEMI 
54% (95% CI 52–56) [14]. This data corresponds with 
ours and likely reflects true adherence. 
Several studies have tried to identify patients who 
fail to follow medical advice on discharge from hospital. 
This knowledge may help the health care professionals 
to develop quality improvement initiatives which target 
this high-risk population in order to improve their out-
comes following AMI [15]. In our study, male gender 
was associated with significantly lower adherence as 
compared with female gender.
Melloni et al. [16] evaluated adherence to med-
ication by means of interviewing 1,077 patients 
after acute coronary syndromes (ACS). At 3-month 
follow-up, 304 patients (28.2%) had discontinued at 
least one of the prescribed medicines. Most cases of 
drug discontinuation (61.5%) were self-determined. 
The factors independently associated with self-dis-
continuation included: having no or limited healthcare 
cover, increasing the number of medications, not using 
reminder tools (e.g., pillbox), lower education status, 
and dialysis [16]. On the basis of patient interviews 
Garavalia et al. [6] defined reasons for non-adherence 
to prescribed medication in patients after AMI. Adverse 
effects that were painful and interfered with daily life 
constituted the most common reason for discontin-
uing the use of medication.. Less common reasons 
for discontinuation were: prescription confusion, cost, 
distrust in medicine, healthcare system, and prefer-
ence for alternative therapies. Reasons for clopidogrel 
discontinuation were duration confusion, adverse 
effects and cost [6]. According to Muntner et al. [17], 
the risk for low clopidogrel adherence was higher in 
patients who reported, prior to PCI, taking smaller 
doses of medication due to cost or had difficulty filling 
prescriptions, had difficulty reaching their primary 
physician, or were uncomfortable asking their doctor 
for advice. Sengstock et al. [18] highlighted the need 
for corrective measures to commence on hospitaliza-
tion and involve practitioners who can follow patients 
after discharge. A solid, ongoing relationship between 
patients, their primary-care physicians and cardiolo-
gists is essential regarding this issue [18]. Taking into 
account the findings from the previous studies, we 
continue with the evidence-based treatment initiated 
in the hospital [10–12, 19]. To build mutual trust, ev-
ery patient was accompanied by the same physician 
during hospitalization and follow-up. Nevertheless, our 
educational intervention failed. 
Ho et al. [20] tested the impact of multifaceted in-
tervention and usual care on adherence to medication 
regimens in 253 patients with ACS. The intervention 
lasted for 1 year following discharge and comprised 
pharmacist-led medication, patient education, collab-
orative care between pharmacist and patient’s primary 
care clinician and/or cardiologist, and 2 types of voice 
messaging (both educational and medication refill re-
minder calls). Using the same definition of primary end-
point that we used, a greater proportion of intervention 
patients adhered to clopidogrel, statins and ACEI/ARB 
but not b-blockers. However, this did not lead to any 
differences in the proportion of patients who achieved 
blood pressure and LDL-cholesterol level goals [20]. 
McDonald et al. [21] performed a systematic review of 
the published randomized controlled trials (RCTs) of 
interventions aimed at assisting patients’ adherence to 
prescribed medications. Interestingly, 49% of the inter-
ventions tested (19 out of 39 in 33 studies) were associ-
ated with statistically significant increases in medication 
adherence and only 17 reported statistically significant 
improvements in the treatment outcomes. Almost all 
the interventions that were effective for long-term care 
were complex, and included combinations of more 
convenient care, information, counseling, reminders, 
self-monitoring, reinforcement, family therapy and other 
forms of additional supervision or attention. Even the 
most effective interventions had modest effects [21].
However, the current analysis has potential limita-
tions. Firstly, this was a single-center study and the 
population was relatively small. Therefore, our findings 
are uncertain and cannot be generalized. Secondly, 
drug availability does not necessarily reflect its actual 
intake. This, however, is a methodological limitation that 
should be taken into account when using this particular 
approach for evaluation of adherence to medication. 
Conclusions
In conclusion, the program of individual health ed-
ucation did not improve adherence to treatment with 
clopidogrel. The expected benefits of medications are 
not available at currently achievable levels of adherence. 
There is a need for further innovative approaches to 
assist patients to follow prescribed medications in order 
to improve health outcomes after AMI. The self-reported 
adherence assessment is unreliable and cannot be 
used for effective treatment guidance. 
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